| pubmed-article:16278416 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16278416 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:16278416 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:16278416 | lifeskim:mentions | umls-concept:C0025914 | lld:lifeskim |
| pubmed-article:16278416 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:16278416 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:16278416 | lifeskim:mentions | umls-concept:C1516211 | lld:lifeskim |
| pubmed-article:16278416 | lifeskim:mentions | umls-concept:C0041365 | lld:lifeskim |
| pubmed-article:16278416 | lifeskim:mentions | umls-concept:C1709630 | lld:lifeskim |
| pubmed-article:16278416 | pubmed:issue | 21 | lld:pubmed |
| pubmed-article:16278416 | pubmed:dateCreated | 2005-11-9 | lld:pubmed |
| pubmed-article:16278416 | pubmed:abstractText | Current prostate cancer research in both basic and preclinical trial studies employ genetically engineered mouse models. However, unlike in human prostate cancer patients, rodents have no counterpart of prostatic-specific antigen (PSA) for monitoring prostate cancer initiation and progression. In this study, we established a mouse serum tumor marker from a mouse homologue of human prostate secretory protein of 94 amino acids (PSP94). Immunohistochemistry studies on different histologic grades from both transgenic and knock-in mouse prostate cancer models showed the down-regulation of tissue PSP94 expression (P < 0.001), the same as for PSA and PSP94 in humans. The presence of mouse serum PSP94 was shown by affinity column and immunoprecipitation purification using a polyclonal mouse PSP94 antibody. A competitive ELISA protocol was established to quantify serum PSP94 levels with a sensitivity of 1 ng/mL. Quantified serum levels of mouse PSP94 ranged from 49.84 ng/mL in wild-type mice to 113.86, 400.45, and 930.90 ng/mL in mouse prostatic intraepithelial neoplasia with microinvasion, well differentiated, moderately differentiated, and poorly differentiated prostate cancer genetically engineered prostate cancer mice, respectively (P < 0.01, n = 68). This increase in serum PSP94 is also well correlated with age and tumor weight. Through longitudinal monitoring of serum PSP94 levels of castrated mice (androgen ablation therapy), we found a correlation between responsiveness/refractory prostate tissues and serum PSP94 levels. The utility of mouse serum PSP94 as a marker in hormone therapy was further confirmed by three-dimensional ultrasound imaging. The establishment of the first rodent prostate cancer serum biomarker will greatly facilitate both basic and preclinical research on human prostate cancer. | lld:pubmed |
| pubmed-article:16278416 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16278416 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16278416 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16278416 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16278416 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16278416 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16278416 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16278416 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16278416 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16278416 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16278416 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16278416 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:16278416 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:16278416 | pubmed:author | pubmed-author:SakaiHidekiH | lld:pubmed |
| pubmed-article:16278416 | pubmed:author | pubmed-author:XuanJim WJW | lld:pubmed |
| pubmed-article:16278416 | pubmed:author | pubmed-author:MoussaMadelei... | lld:pubmed |
| pubmed-article:16278416 | pubmed:author | pubmed-author:ChinJoseph... | lld:pubmed |
| pubmed-article:16278416 | pubmed:author | pubmed-author:GreenbergNorm... | lld:pubmed |
| pubmed-article:16278416 | pubmed:author | pubmed-author:LacefieldJame... | lld:pubmed |
| pubmed-article:16278416 | pubmed:author | pubmed-author:FensterAaronA | lld:pubmed |
| pubmed-article:16278416 | pubmed:author | pubmed-author:WuGuojunG | lld:pubmed |
| pubmed-article:16278416 | pubmed:author | pubmed-author:HuizenIsaac... | lld:pubmed |
| pubmed-article:16278416 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16278416 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:16278416 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:16278416 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16278416 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16278416 | pubmed:pagination | 7911-9 | lld:pubmed |
| pubmed-article:16278416 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:meshHeading | pubmed-meshheading:16278416... | lld:pubmed |
| pubmed-article:16278416 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16278416 | pubmed:articleTitle | Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models. | lld:pubmed |
| pubmed-article:16278416 | pubmed:affiliation | Department of Surgery, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada. | lld:pubmed |
| pubmed-article:16278416 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16278416 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16278416 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| entrez-gene:17695 | entrezgene:pubmed | pubmed-article:16278416 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16278416 | lld:pubmed |
